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ABSTRACT 
The present work was aimed to formulate Superporous Hydrogel tablets of Nimodipine using an effervescent approach for gastro retentive 
drug delivery system to improve its bioavailability by using different rate retarding polymers like plantago ovata, tamarind gum and carbopol, 
along with suitable excipients. All the formulations were prepared by direct compressionmethod. The prepared tablets of all the formulations 
were evaluated for physical characteristics, in‐vitro drug release, hardness and friability. Optimized formulation F8 containing 0.3% of plantago 
ovata and carbopol each was considered as the best formulation with respect to in vitro drug release for 12 hours release act ion. The results 
showed that the drug release rate was decreased as the viscosity of the polymer was increased. The drug release kinetics was performed for the 
optimized formulation and it shows zero orderwith non-fickian transport drug release. 
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INTRODUCTION 
Nimodipine is a 1,4-dihydropyridine calcium channel blocker 
originally developed for the treatment of high blood 
pressure. It acts primarily on vascular smooth muscle cells 
by stabilizing voltage-gated L-type calcium channels in their 
inactive conformation. By inhibiting the influx of calcium in 
smooth muscle cells, nimodipine prevents calcium-
dependent smooth muscle contraction and subsequent 
vasoconstriction. Compared to other calcium channel 
blocking agents, nimodipine exhibits greater effects on 
cerebral circulation than on peripheral circulation. 
Nimodipine is used to act as an adjunct to improve the 
neurologic outcome following subarachnoid hemorrhage 
from ruptured intracranial aneurysm1-6. 
Superporous hydrogels (SPHs) were originally developed as 
a novel drug delivery system to retain drugs in the gastric 
medium. These systems should instantly swell in the 
stomach and maintain their integrity in the harsh stomach 
environment, while releasing the pharmaceutical active 
ingredient. A superporous hydrogel (SPH) is a three-
dimensional network of a hydrophilic polymer that absorbs a 
large amount of water in a very short period of time due to 
the presence of interconnected microscopic pores.Maximum 
swelling is generally reached in a fraction of a minute with 
SPHs having average pores of 200mm in size. When applied 
as drug carriers, these highly swollen hydrogels remain in 
stomach for a long time, releasing almost all loaded drugs, 
since their volumes are too big to transport through the 
pylorus and their sheer bulk hinder their transport to the 
next organ via the narrow pylorus. This unique swelling 
property allows them to be used as gastric retention carriers 
providing a sustained release through long residence in the 
stomach. In order to be used as an effective gastric retention 
device, the hydrogels are required to possess not only fast 
swelling but also following properties: biocompatibility, 
biodegradability, high swelling capacity, high mechanical 
strength, and stability in acidic condition7-11. 
Superporous hydrogels are one of the important approaches 
to achieve gastric retention to obtain sufficient drug 
bioavailability. This delivery system is desirable for 
enhancing the bioavailability and produce prolonged action 
in GIT. Orally-administered Nimodipine is rapidly and 
completely absorbed from the gastrointestinal tract8, 12-17. 
This approach includes the development of Nimodipine 
Super porous Hydrogel tablets. Nimodipine is a calcium 
channel blocker which is originally developed in the 
treatment of high blood pressure.Nimodipine has a half-life 
of 8-9 h, the bioavailability of 13% and it has narrow 
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absorption window in upper part of the gastrointestinal tract 
(GIT), hence gastric drug delivery system (GDDS) is 
preferred for enhanced absorption and increased 
bioavailabilty of the drug15, 18, 19. 
MATERIALS AND METHODS 
Materials: 
Nimodipine purchased from Biophore India pharmaceutical 
Pvt.Ltd Hyderabad, Plantago ovata, Tamarind gum, Carbopol, 
Sodium bicarbonate, Citric acid, Glyoxal, PVA, Magnesium 
stearate, Talc, Micro crystalline cellulose and Hydrochloric 
acid were used. All the reagents used are of LR grade.  
Method of Preparation of Tablets: 
The drug loaded SPHs are prepared by direct compression 
method: 
Hydrocolloid polymer solution (1%w/v) was prepared by 
stirring in distilled water using a homogenizer until the 
polymer dissolves in distilled water completely. A 1% w/w 
aqueous PVA solution was prepared and mixed to the 
polymer solution. To this solution, 0.2% of Glyoxal (10% 
w/w of the dry weight of polymers) was mixed thoroughly 
followed by 50 mg of sodium bicarbonate & 25mg of citric 
acid. The prepared mixture was stirred well and kept aside 
overnight. 10 ml of 0.1 N HCL was taken to this 30 mg of drug 
and 100 mg of superporous hydrogel were added and mixed 
for 1 h at 50°C. Then acetone of 2ml was added and the 
hydrogel was repeatedly washed with distilled water to 
remove any unreacted material. Further it was dried at 40°C 
for 24h, finally powdered and stored in a well closed 
container.  
Preformulation Studies: 
Determination of absorption maximum (λmax)19, 20: 
Accurately weighed 10mg of Nimodipine was dissolved in 
0.1N Hcl (pH 1.2) taken in a clean 10ml volumetric flask. The 
volume was made up to 10ml with 0.1N Hcl which will give 
stock solution-I with concentration 1000µg/ml. From the 
stock solution-I, 1ml was pipette out in 10ml volumetric 
flask. The volume was made up to 10ml using 0.1N Hcl to 
obtain stock solution-II with a concentration 100µg/ml. 
From stock solution-II, 1ml was pipette out in 10ml 
volumetric flask. The volume was made up to 10ml using 
0.1N Hcl to get a concentration of 10µg/ml. This solution was 
then scanned at 200-400nm in UV-Visible double beam 
spectrophotometer to attain the absorption maximum 
(λmax).  
Construction of calibration curve using 0.1 N HCL (pH 
1.2) 19, 20: 
Standard calibration curve of Nimodipine in buffer pH 1.2: 
 Standard solution: Accurately weighed 10mg of 
Nimodipine was dissolved in methanol taken in a clean 
10ml volumetric flask. The volume was made up to 
10ml with methanol which gives a concentration of 
1000µg/ml. 
 Stock solution:  From this standard solution, 1ml was 
pipette out in 10ml volumetric flask and volume was 
made up to 10ml using 0.1N Hcl to obtain a 
concentration of 100µg/ml. From the above stock 
solution, aliquots of 0.5, 1, 1.5, 2, 2.5 and 3 ml each was 
transferred to a separate 10ml volumetric flask and 
solution was made up to 10ml using 0.1N Hcl to obtain 
a concentration of 5, 10, 15, 20, 25 and 30µg/ml 
respectively. The absorbance of each solution was 
measured at 292nm. 
Drug excipient compatibility study: 19, 20 
The drug and excipient compatibility was observed using 
Fourier Transform – Infra Red spectroscopy (FT-IR). The FT-
IR spectra obtained from Bruker FT-IR Germany (Alpha T) 
was utilized in determining any possible interaction between 
the pure drug and the excipients in the solid state. The 
potassium bromide pellets were prepared on KBr press by 
grounding the solid powder sample with 100 times the 
quantity of KBr in a mortar. The finely grounded powder was 
then introduced into a stainless steel die and was 
compressed between polished steel anvils at a pressure of 
about 8t/in2. The spectra were recorded over the wave 
number of 8000 to 400cm-1. 
Flow properties: 19, 20, 21 
(Precompression Parameters): 
1. Angle of repose: Angle of repose is defined as the 
maximum angle possible between the surface of a pile of the 
powder and the horizontal plane. The flow characteristics 
are measured by angle of repose. A specific amount of 
powder was collected in a glass funnel by blocking the orifice 
with thumb at the stem opening. The funnel was fixed at a 
height of 2cm from a horizontal plate. After the adjustment is 
done the thumb is removed and the powder is allowed to 
flow over the plate to form a pile. The height of the pile was 
noted. A Circumference was drawn with a pencil on a graph 
paper and the radius of base of a pile was measured at 5 
different points and average was taken for calculation. 
          
Therefore, 
           
Where   h = height of pile. 
  r = radius of the base of the pile. 
  θ = angle of repose. 
Table No.1.1: Flow Properties and corresponding angles 
of repose 
Flow Property  Angle Of Repose (degrees) 
Excellent 25 – 30 
Good 31 – 35 
Fair (aid not needed) 36 – 40 
Passable (may hang up) 41 – 45 
Poor (must agitate, vibrate) 46 – 55 
Very poor 56 – 65 
Very, Very poor > 66 
 
2. Bulk density:  The bulk density of a powder is the ratio of 
the mass of an untapped powder sample and its volume 
including the part of the interparticulate void volume. A 
definite amount of blend was transferred carefully to 
measuring cylinder which was initially passed through sieve 
no: 20. It is expressed as gm/ml and calculated using the 
equation19, 21. 
                                     Ρ = W/Vb 
Where  Ρ = bulk density. 
    W = mass of the powder blend. 
 Vb = bulk volume of powder blend. 
3. Tapped density: Tapped density is the ratio of mass of 
powder to the tapped volume. Tapped volume is the volume 
occupied by the same mass of powder after a standard 
tapping of measure. 19, 20 
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A certain amount of powder (about 5gm) was passed 
through sieve no: 22 and transferred to the graduated 
cylinder fixed on the bulk density apparatus. The timer knob 
was set for 50 tapping and the volume was noted after the 
specified taps. The process of tapings was continued until 
concurrent volume is achieved. This final volume is tapped 
volume and the tapped density was calculated using the 
following equation and expressed as gm/ml.  
Ρb, max = W/V50 
Where  Ρb, max = tapped density. 
  W = mass of the powder blend. 
  V50 = volume of powder blend at 50 taps. 
4. Carr’s consolidation Index: This property is also known 
as compressibility. It is indirectly related to the relative flow 
rate, cohesiveness and particle size. It is simple, fast and 
popular method of predicting powder flow characteristics. It 
was calculated by using following formula: 
 
 
Table No.1.2: Carr’s index as an indication of granule 
flow properties 
% CI Properties 
5-12 Free flowing 
12-16 Good 
18-21 Fair 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
 
5. Hausner’s ratio: A similar index has been defined by 
hausner in order to determine the flow property. Hausner’s 
ratio greater than 1.25 is considered to be an indication of 
poor flowability. It was calculated by using following 
formula: 
 
Table No.1.3: Hausner ratio as an indication of granule 
flow properties 
Hausner ratio Properties 
1.00 – 1.11 Excellent 
1.12 – 1.18 Good 
1.19 – 1.25 Fair 
1.26 – 1.34 Passable 
1.35 –1.45 Poor 
1.46 – 1.59 Very poor 
> 1.60 Extremely poor 
 
Post compression parameters 18, 19, 20: 
Tablets are evaluated for its parameters like various quality 
control tests such as Tablet thickness and Diameter, 
Hardness, Friability, uniformity of weight and content 
uniformity of drug and other specific evaluation tests for 
GRDDS like swelling studies & release rate of drug. 
1) Tablet thickness and Diameter:  
Thickness and diameter of tablets were important for 
uniformity of tablet size. Thickness and diameter were 
measured using Vernier calipers. The tablet thickness should 
be controlled within a ± 5% variation of a standard value. 
The thickness of the tablet is mostly related to the tablet 
hardness can be uses as initial control parameter. It is 
expressed in millimeters (mm). 
2) Weight variation: 
Ten tablets were selected randomly from each batch were 
weighed individually and together in a single pan balance. 
The average weight was noted and standard deviation 
calculated. The tablet passes the test if not more than two 
tablets fall outside the percentage limit and none of the 
tablet differs by more than double the percentage limit. 
           
                        
             
     
Table No.1.4: IP Standard values of % deviation 
Average weight % deviation 
80mg or less 10 
More than 80mg but less than 250mg 7.5 
250mg or more 5 
 
3) Hardness:  
Tablet hardness has been defined as the force required break
ing a tablet in adiametric compression test. The hardness of 
the tablets was determined using pfizer hardness tester 
(cisco). Six tablets were picked randomly from each 
formulation for measurement. It is expressed in Kg/cm2.  
4) Friability: 
The friability test was carried out to evaluate tablet surfaces 
and/or show evidence of lamination or capping when 
subjected to mechanical shock or attrition. The friability of 
tablets was determined by using Roche friabilator (Lab India, 
FT 1020) and expressed in %. Ten tablets dedusted tablets 
were initially weighed [W(initial)] and transferred to friabilator 
and are subjected to fall from 6 inches height. After 
completion of 100 rotations i.e., 25 rpm for 4 minutes, the 
tablets were weighed again [W(final)]. The friability (f) was 
calculated by the formula 
 
Values from 0.8-1.0% are regarded as the upper limit of 
acceptability 
5) Drug content uniformity: 
The test is used to ensure that every tablet contains the 
amount of drug intended with little variation among tablets 
within a batch. From each batch of the formulation, 10 
tablets were collected randomly and powered using a mortar 
and pestle. A quantity of the powder equivalent to the weight 
of one tablet (100mg drug) was transferred to a 100ml 
volumetric flask. The powder equivalent to 100mg drug was 
dissolved in 1.2 ph buffer and volume was made up to 100ml 
to give a concentration of 1000µg/ml. 1ml of this solution 
was taken and diluted to 10ml to give a concentration of 
100µg/ml. The absorbance of the prepared solution was 
measured at 263 nm using UV Visible spectrophotometer 
(PG Instruments T60) and the drug concentration was 
determined from the standard calibration curve by using the 
regression equation. The preparation passes the test if 
individual drug content is 85-115% of the average content. 
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6) Swelling studies18-22: 
i) Swelling Study: 
The dried superporous hydrogel (100 mg) was immersed in 
excess of the swelling medium (20 ml) at 37oC. The swelling 
behavior of a dosage form was measured by studying its 
weight gain or water untake the dimensional changes could 
be measured in terms of the increase in tablet diameter 
and/or thickness over time. Water uptake was measured in 
terms of percent weight gain, as given by the equation. 
WU = (W1 – W0) x 100 
--------------                                   
W0 
Wt= Weight of dosage form at time t. 
W0 = Initial weight of dosage form 
ii) Measurement of density of superporous hydrogel: 
The density (d) of the dried hydrogels was calculated. 
d = Wd/Vd 
where, 
Wd = weight of dried hydrogel and Vd = volume.  
The volume of the hydrogel was determined by the solvent 
displacement method using hexane as the displacement fluid. 
Hexane was used because it is very hydrophobic and 
superporous hydrogels do not absorb it.  
iii) Porosity measurement: 
For porosity measurement, the solvent replacement method 
was used. Dried hydrogels were immersed overnight in 
absolute ethanol and weighed after excess ethanol on the 
surface was blotted. The porosity was calculated from the 
following equation: 
Porosity = (M2 – M1) / ρV 
Where M1 and M2 are the mass of the hydrogel before and 
after immersion in absolute ethanol, respectively;  
ρ is the density of absolute ethanol and V is the volume of the 
hydrogel. 
iv) Determination of void fraction: 
The void fraction was calculated by the following equation: 
Void Fraction =  
Dimensional volume of the hydrogel / Total volume of pores 
The void fraction inside superporous hydrogels was 
determined by immersing the hydrogels in HCl solution (pH 
1.2) up to equilibrium swelling. The dimensions of the 
swollen hydrogels were measured and by using these data, 
sample volumes were determined as the dimensional 
volume. In the meantime, the amount of absorbed buffer into 
the hydrogels was determined by subtracting the weight of 
dried hydrogel from the weight of swollen hydrogel and the 
resulting values were assigned as the total volume of pores 
in the hydrogels. 
v) Water retention:  
The following equation was used to determine the water 
retention capacity (WRt) as a function of time:  
WRt = (Wp - Wd) / (Ws - Wd) 
Where, 
Wd = weight of the dried hydrogel, Ws = weight of the fully 
swollen hydrogel, and 
Wp = weight of the hydrogel at various exposure times. 
For determination of the water-retention capacity of the 
hydrogels as a function of the time of exposure at 37 oC, the 
water loss of the fully swollen polymer at timed 
intervals was determined by gravimetry. 
7) Scanning electron microscopy: 
The dried superporous hydrogels were used for scanning 
electron microscopy (SEM) studies to determine the 
morphology of the dried samples. A JEOL JSM-840 scanning 
electron microscope (Jeol USA, Inc., Peabody, MA) was used 
after coating the samples with gold using a Hummer Sputter 
Coater (Technics, Ltd.). Images were captured using a digital 
capture card and Digital Scan Generator 1 (JEOL). 
8) In-vitro Drug release studies: 
In-vitro drug release of the samples was carried out using 
USP– type II dissolution apparatus (paddle type).  The 
dissolution medium, 900 ml 0.1N Hcl solution, was placed 
into the dissolution flask maintaining the temperature of 37 
+ 0.5oC using 50 rpm.  One Nimodipine tablet was placed in 
each paddle of dissolution apparatus.  The apparatus was 
allowed to run for 12hours.  Samples measuring 5 ml were 
withdrawn at regular intervals upto 12 hours using 5 ml 
syringe. The fresh dissolution medium (37oC) was replaced 
every time with the same quantity (5ml) of dissolution 
medium.  Collected samples were suitably diluted with 0.1N 
Hcl and analyzed at 263 nm using 0.1N Hcl as blank by using 
a double beam UV spectrophotometer (T60 UV-VISIBLE 
spectrophotometer). The cumulative percentage drug 
release was calculated. The graphs of time vs % release were 
plotted.To ascertain the order and mechanism of drug 
release the in vitro release data was 
subjected to various kinetic equations. 
Kinetic Models22-26: 
Treatment of dissolution data with different kinetic 
equations:  
To analyze the mechanism of release and release rate kinetics of the dosage 
form, the data obtained were fitted into Zero order, First order, Higuchi 
matrix,and Peppas.Based on the  r- value, the best-fit model was selected. 
1)Zero Order Kinetics: 
A zero-order release would be predicted by the following 
equation: 
dQ/dt = K0 
Where,          Q = Drug released at time ‘t’ 
                      K0= Zero-order rate constant (h-1). 
When the data is plotted as cumulative percent drug released 
versus time, if the plot is linear then the data obeys zero-order 
release kinetics, with a slope equal to K0. 
2)First Order Kinetics: 
To study the first order release rate kinetics, the release rate data 
were fitted to the following equation: 
dQ/dt = K1Q 
Where,        Q = Amount of drug remained at time ‘t’ 
                     K1 = First-order rate constant (h-1). 
When the data is plotted as log cumulative percent drug 
remaining versus time; yields a straight line, indicating that the 
release follows first-order kinetics. The constant ‘K1’ can be 
obtained by multiplying 2.303 with slope values. 
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3)Higuchi model23: 
Higuchi developed several theoretical models to study the 
release of water soluble and low soluble drugs incorporated 
in semisolids and/or solid matrices. Mathematical 
expressions were obtained for drug particles dispersed in a 
uniform matrix behaving as the diffusion media. And the 
equation is,  
Qt = KH ·t
1/2
 
Where, Qt = amount of drug released in time t, 
KH = Higuchi dissolution constant 
4) Korsmeyer and Peppas model25: 
The release rate from sustained release polymeric matrices 
can be described by 
the equation proposed by korsmeyer et al. 
                                                        Q = KKPtn 
Where, Q = The amount of drug released at time ‘t’ 
KKP = Kinetic constant incorporating structural and 
geometric characteristics of the tablets 
‘n’ = The diffusional exponent, indicative of the release 
mechanism. 
The release exponent, n, is the slope of log fraction of drug 
release versus log time curve. 
Comparision with Marketed Product: 
The dissolution time of optimized tablets were compared 
with marketed product Nimotop 30mg. 
RESULTS AND DISCUSSION 
Solubility study: 
From the solubility studies it was observed that Nimodipine 
wasfoundtobemore soluble in 0.1N HCL pH1.2 buffer. 
Melting point determination: 
The melting point of  Nimodipine was found to be 7⁰C 
Determinationofλmax 
Wave length of maximum absorption of Nimodipine was 
found to be 263.40nm in 0.1N HCL buffer. 
Calibration curve of Nimodipne at λmax of 263.40nm 
Standard calibration data of Nimodipine was performed in 
0.1N HCL. 
Drug excipientinteraction (FTIR) study 
FTIR Spectra were obtained for Nimodipine physical 
mixture, Nimodpine and excipients. The characteristic peaks 
of the Nimodipine were  compared  with  the peaks  obtained 
for physical mixture of Nimodipine and excipients. From the 
obtained spectra it appeared that there were no interaction 
between Nimodipine and excipients. 
Surfacemorphology(SEM) 
ThesurfacemorphologyoftheNimodipinetablets 
wasstudiedby SEM.SEM photographsof the 
optimizedformulationwere shown inthe Fig.1.5. Surface 
morphology of the formulated hydrogel indicates the porous 
nature of the hydrogel showing 10µ range. 
Invitro dissolution studies: 
From the invitro drug release studies it was observed that 
the formulations of gastro retentive superporus hydrogel 
tablets of Nimodipine formulated by using Plantago Ovata, 
Carbopol& Tamarind gum. The invitro performance 
ofNimodipine superporous hydrogel tablets showed 
sustained release of Nimodipine.  As the polymer 
concentration was increased, the drug release from the 
hydrogels was found to decrease. Compared to 
Plantagoovata & tamarind  gum, tamarind gum and carbopol, 
plantago ovate & carbopol shows optimum drug release at 
the end of 12 hours. The invitro release profiles of all the 
formulations(F1toF9) are shown in tables1.11 and Fig. 1.6to 
1.9. 
Release kinetics of Nimodipine superporous hydrogel 
tablets: 
The invitro dissolution data for best formulation F8were 
fitted in different kinetic models i.e, zero order, first order, 
Higuchi and korsemeyer-peppas equation. Optimized 
formulation F8 shows R2 value0.973. As its value nearer to 
the ‘1’ it is conformed as it follows the zero order release. 
The mechanism of drug release is further confirmed by the 
Higuchi and peppas plot. 
The ‘n’ value is 0.865 for the optimizedformulation (F8) i.e., n 
value was <0.89 this indicates non-fickian transport. 
Comparision with Marketed product: 
The dissolution time of optimized tablets were compared 
with marketed product Nimotop 30mg and optimized 
formulation F8 shown better dissolution profile compared 
with marketed tablets as shown in Table:1.13. 
Table No.1.5: Wavelengthofmaximum absorptionof 
Nimodipine in 0.1N Hcl(pH1.2) buffer 
Serial No: Solvent λmax 
1 0.1N Hcl 263.40 
 
Determination of absorption maximum (λmax): 
 
Fig 1.1: UV spectrum of Nimodipine 
Table No.1.6: Standard graph of Nimodipine in 0.1 N Hcl (pH  
1.2) 
Concentration(µg/ml) Absorbance 
0 0 
5 0.123±0.08 
10 0.246±0.07 
15 0.386±0.02 
20 0.529±0.10 
25 0.663±0.06 
30 0.802±0.02 
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Fig 1.2: Calibration curve  of Nimdipine 
using 0.1 N Hcl (pH 1.2): 
Table No.1.7: Formulations of Superporous hydrogel tablets of Nimodipine Prepared by Direct compression Method 
Ingredients(mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Nimodipine wt.equivalent 
to 30mg 
30 30 30 30 30 30 30 30 30 
sGlyoxal(%) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
PVA(%) 1 1 1 1 1 1 1 1 1 
Plantago Ovata(%) 0.1 0.1 - 0.2 0.2 - 0.3 0.3 - 
Tamarind gum(%) 0.1 - 0.1 0.2 - 0.2 0.3 - 0.3 
Carbopol(%) - 0.1 0.1 - 0.2 0.2 - 0.3 0.3 
NAHCO3 50 50 50 50 50 50 50 50 50 
Citric acid 25 25 25 25 25 25 25 25 25 
MCC Q.S Q.S Q.S Q.S Q.S Q.S Q.S. Q.S Q.S 
Mg.stearate 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
Talc 5 5 5 5 5 5 5 5 5 
Tablet weight(mg) 250 250 250 250 250 250 250 250 250 
 
Drug excipient compatibility: 
Drug and excipient compatibility was confirmed by comparing spectra of FTIR analysis of pure drug with that of various 
excipients used in the formulation. 
 
Fig 1.3: FT-IR spectra of pure drug 
 
Fig 1.4: FTIR Spectra of optimized formulation 
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Flow Properties: 
Pre compresssion parameters: 
Table No 1.8: Flow properties of tablet blend. 
Formulation 
code 
Angle of repose 
(θ) 
Tapped density 
(gm/ml) 
Bulk density 
(gm/ml) Carr’s index (%) Hausner’s ratio 
F1 31.17±0.56 0.526±0.25 0.456±0.23 13.31±0.20 1.15±0.54 
F2 30.16±0.14 0.539±0.44 0.461±0.43 14.47±0.43 1.17±0.17 
F3 29.52±0.85 0.548±0.81 0.438±0.52 20.07±0.56 1.25±0.78 
F4 30.47±0.23 0.586±0.59 0.493±0.86 15.87±0.89 1.19±0.85 
F5 27.69±0.95 0.529±0.96 0.429±0.95 18.90±0.98 1.23±0.51 
F6 28.53±1.05 0.514±0.65 0.415±0.68 19.26±0.65 1.24±0.98 
F7 30.42±0.85 0.539±0.18 0.448±0.37 16.88±0.11 1.20±0.65 
F8 33.18±0.23 0.514±0.64 0.439±0.14 14.59±0.54 1.17±0.34 
F9 31.15±0.61 0.538±0.32 0.451±0.41 16.17±0.42 1.19±0.22 
 
Post compression parameters 
Table No 1.9: Evaluation of Prepared Nimodipine Superporous Hydrogel Tablets. 
Formulation 
Code 
Hardness 
(Kg/cm2) 
Thickness (mm) Friability% 
Weight 
variation (%) 
Drug content 
(%) 
F1 6.6±0.18 4.2 ± 0.17 0.268±0.29 249.2±0.82 89.78±0.15 
F2 6.4±0.28 3.3 ± 0.09 0.175±1.02 248.2±0.89 92.63±0.52 
F3 6.8±0.56 3.0 ± 0.04 0.569±0.16 247.8±0.53 90.48±0.48 
F4 6.2±0.17 3.6 ± 0.06 0.684±0.18 249.1±0.73 87.52±0.96 
F5 7.2±0.53 3.2 ± 0.32 0.790±0.75 246.8±0.52 96.75±0.17 
F6 6.8±0.29 3.6 ± 0.06 0.631±0.56 248.4±0.48 92.56±0.26 
F7 6.9±0.17 4.3 ± 0.12 0.523±0.15 251.6±0.96 98.48±0.18 
F8 6.1±0.28 3.7± 0.01 0.609±0.36 247.6±0.82 99.36±0.63 
F9 6.5±0.36 3.9± 0.06 0.694± 0.84 246.8±0.96 96.15±0.45 
 
Swelling Index: 
Table No.1.10: Swelling Index of dried SPH’s 
Formulations Swelling index(%) Porosity (%) Void fraction (ml/g) 
F1 47.35 ± 0.23 40.22 ± 0.28 0.59 ± 0.03 
F2 58.00 ± 0.14 62.84 ± 0.36 0.62 ± 0.04 
F3 44.28 ± 0.18 58.49 ± 0.54 0.52 ± 0.01 
F4 52.60 ± 0.80 52.69 ± 0.58 0.74 ± 0.03 
F5 68.75 ± 0.56 71.82 ± 0.22 0.84 ± 0.02 
F6 59.50 ± 0.20 69.16 ± 0.36 0.69 ± 0.04 
F7 62.80 ± 0.26 64.86 ± 0.72 0.80 ± 0.03 
F8 79.40 ± 0.32 80.02 ± 0.48 0.91 ± 0.01 
F9 66.28 ± 0.16 72.66 ± 0.76 0.88 ± 0.03 
 
Sem Analysis: 
 
Fig.1.5: Surface morphology of the formulated hydrogel indicates the porous nature of the hydrogel showing 10µ range. 
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Dissolution Studies: 
Table No.1.11: Cumulative % drug release profile of Nimodipine Superporous Hydrogel tablets prepared by Direct 
Compression Method 
Time 
(hrs) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
0.5 36.85±0.26 22.95±0.22 26.85±0.53 32.63±0.21 18.63±0.68 23.62±0.88 26.49±0.06 16.28±0.13 17.62±0.20 
1 42.19±0.48 29.65±0.13 33.49±0.16 46.85±0.64 26.85±0.06 29.05±0.92 36.16±0.52 26.84±0.26 30.84±0.12 
2 52.96±0.54 39.84±0.02 42.85±0.25 53.95±0.26 30.48±0.42 36.48±0.16 42.16±0.78 32.10±0.101 37.13±0.71 
3 60.48±0.14 52.63±0.32 59.63±0.60 59.16±0.13 46.28±0.14 50.18±0.34 49.63±0.40 39.62±0.54 42.85±0.85 
4 76.08±0.53 69.18±0.64 70.62±0.33 62.96±0.42 52.49±0.30 59.06±0.52 56.59±0.26 46.18±0.22 50.63±0.96 
5 82.64±0.96 75.49±0.11 76.18±0.92 75.36±0.50 60.85±0.62 65.82±0.78 63.08±0.91 52.06±0.38 59.82±0.63 
6 99.45±0.82 86.39±0.56 89.62±0.50 82.95±0.61 69.16±0.96 76.89±0.44 70.63±0.15 59.76±0.63 66.18±0.31 
7  99.82±0.13 97.06±0.81 91.54±0.90 81.54±0.88 89.04±0.62 79.84±0.30 66.19±0.91 70.49±0.08 
8   101.02±0.81 98.38±0.80 80.32±0.54 98.97±0.20 87.63±0.06 70.36±0.80 79.52±0.56 
9     89.06±0.12  92.06±0.15 78.62±0.52 83.16±0.72 
10     97.63±0.02  99.54±0.52 85.86±0.40 90.12±0.14 
11     100.02±0.48   90.54±0.12 99.26±0.26 
12        98.62±0.23  
 
In-Vitro Drug Release of F1-F9 
 
Fig.1.6: In Vitro Drug Release Of F1-F9 
 
Fig.1.7: In Vitro Drug Release Of F1-F3 
 
Fig.1.8: In Vitro Drug Release Of F4-F6 
 
 
Fig.1.9: In Vitro Drug Release Of F7-F9 
Drug Release Kinetics: 
ZERO ORDER:  
 
Fig.1.10: Zero order graph of optimized formulation 
FIRST ORDER:  
 
Fig.1.11: first order graph of optimized formulation 
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H IGUCHI:  
 
Fig.1.12: Higuchi graph of optimized formulation 
PEPPAS:  
 
Fig.1.13: Peppas graph of optimized formulation
 
Table No.1.12: Drug release kinetics of optimized formulation(F8) 
R2 values n values 
Formulation Zero order First order Higuchi 
Korsmeyer – 
Peppas 
Korsmeyer- 
Peppas (n) 
F8 0.973 0.782 0.981 0.561 0.865 
 
Table No.1.13: Comparision with Marketed product 
Time(hrs) Optimized 
Formulation(F8) 
Nimotop 30mg 
0 0 0 
0.5 16.28±0.13 62.63±0.76 
1 26.84±0.26 97.41±0.08 
2 32.10±0.10  
3 39.62±0.54  
4 46.18±0.22  
5 52.06±0.38  
6 59.76±0.63  
7 66.19±0.91  
8 70.36±0.80  
9 78.62±0.52  
10 85.86±0.40  
11 90.54±0.12  
12 98.62±0.23  
 
CONCLUSION 
The results obtained conclusively demonstrated that 
Superporous Hydrogel tablets of Nimodipine were effectively 
prepared with desired properties. Superporous Hydrogel 
tablets of Nimodipine were prepared by direct compression 
method. The directly compressed formulations exhibited 
better in-vitro drug release profiles. The formulation F8 
prepared by direct compression containing combination of 
polymers (i.e., plantago ovate and carbopol)-Glyoxal 
prepared by cross-linking technique exhibited good swelling 
index and maximum rate of drug release. So, this formulation 
was considered to be the optimized formulation. The 
prepared tablet formulations are evaluated for different pre-
compressional and post compressional parameters the 
results revealed that the all formulations shows good 
precompressional properties showing better flowability, 
hardness is maintained in the range of 6.1-7.2kg/cm2 which 
provides good mechanical strength to the tablet. Other 
parameters like weight variation, friability, thickness, drug 
content are in the range of prescribed limits of IP. Thus the 
formulated Superporous Hydrogel tablets of Nimodipine 
offer a superior alternative over conventional marketed 
dosage forms in regards of Localized action and Sustained 
release of drug. FTIR studies combined with stability studies 
proved the integrity of the developed tablets along with sem 
analysis gives improved information of the formulation by 
showing porous formation. Therefore the prepared tablets 
shows improved bioavailability with increased drug release 
time. 
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